Zai Lab Ltd ADR (ZLAB)

Jun 2, 2025, 7:00 AM EDT - 10 hours ago

Zai Lab Presents Positive Phase 1 Data for ZL-1310, a DLL3-Targeted ADC, Demonstrating Robust Anti-Tumor Activity and Safety in Patients with Extensive-Stage Small Cell Lung Cancer at 2025 ASCO Annual Meeting

May 31, 2025, 3:08 PM EDT - 2 days ago

Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting

NVCR

May 30, 2025, 7:30 AM EDT - 3 days ago

Zai Lab Announces Participation in Investor Conferences in June 2025

May 28, 2025, 2:48 AM EDT - 5 days ago

Zai Lab Limited Is Well Positioned For Long-Term Growth

May 22, 2025, 11:25 AM EDT - 11 days ago

Zai Lab Limited: Banking On Chinese Pharma Growth

May 19, 2025, 7:00 AM EDT - 14 days ago

Zai Lab Receives U.S. FDA Fast Track Designation for ZL-1310, a DLL3-Targeted Antibody-Drug Conjugate, for Treatment of Extensive-Stage Small Cell Lung Cancer

May 11, 2025, 8:55 AM EDT - 22 days ago

Zai Lab Limited (ZLAB) Q1 2025 Earnings Call Transcript

May 8, 2025, 6:00 AM EDT - 25 days ago

Zai Lab Announces First Quarter 2025 Financial Results and Recent Corporate Updates

Apr 25, 2025, 1:12 PM EDT - 5 weeks ago

Zai Lab Presents Data Highlighting Potential of Internally Developed, Next-Generation Oncology Therapies at AACR 2025

Apr 23, 2025, 10:56 AM EDT - 5 weeks ago

Zai Lab to Present Data from Phase 1 Trial of DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310 at 2025 ASCO Annual Meeting

Apr 21, 2025, 7:30 AM EDT - 6 weeks ago

Zai Lab Announces Acceptance of Supplemental New Drug Application for Repotrectinib for Patients with NTRK-Positive Solid Tumors

Mar 26, 2025, 7:00 AM EDT - 2 months ago

Zai Lab to Present New Data from Internally Developed, Next-Generation Oncology Candidates at AACR 2025 Annual Meeting

Mar 21, 2025, 5:16 PM EDT - 2 months ago

Zai Lab: Innovative Pharma Set For Strong Year Of Business (And Share Price) Growth

Mar 20, 2025, 1:05 PM EDT - 2 months ago

Zai Lab: Still Attractive Despite Higher Costs And Added Trade War Risks

Mar 12, 2025, 7:30 PM EDT - 2 months ago

Zai Lab Announces Acceptance of Biologics License Application for TIVDAK for the Treatment of Patients with Recurrent or Metastatic Cervical Cancer

Mar 3, 2025, 7:30 AM EST - 3 months ago

Zai Lab Announces Participation in Investor Conferences in March 2025

Feb 27, 2025, 10:46 PM EST - 3 months ago

Zai Lab Limited (ZLAB) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 6:00 AM EST - 3 months ago

Zai Lab Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Updates

Jan 28, 2025, 7:30 AM EST - 4 months ago

Zai Lab to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Recent Corporate Updates on February 27, 2025

Jan 22, 2025, 11:15 PM EST - 4 months ago

Zai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the Treatment of Small Cell Lung Cancer (SCLC)

Jan 17, 2025, 7:30 AM EST - 4 months ago

Zai Lab Announces Acceptance of New Drug Application for KarXT for the Treatment of Schizophrenia

Jan 15, 2025, 7:30 AM EST - 4 months ago

Zai Lab Announces Positive Topline Results for TIVDAK in the China Subpopulation of the Global Phase 3 innovaTV 301 Trial in Patients with Recurrent or Metastatic Cervical Cancer

Jan 10, 2025, 7:30 AM EST - 5 months ago

Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore

VRTX

Jan 10, 2025, 7:30 AM EST - 5 months ago

Zai Lab and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore

VRTX

Jan 9, 2025, 6:30 PM EST - 5 months ago

Zai Lab Announces Strategic Partnership with MediLink Therapeutics to Develop a Novel LRRC15 Antibody-Drug Conjugate

Dec 26, 2024, 2:31 PM EST - 5 months ago

Zai Lab: Rapidly Improving Outlook Bodes Well For The Future

Dec 12, 2024, 7:30 AM EST - 6 months ago

Zai Lab Announces Participation in Investor Conference in January 2025

Dec 2, 2024, 7:02 AM EST - 6 months ago

Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer

NVCR

Nov 27, 2024, 11:05 PM EST - 6 months ago

Zai Lab Announces the Inclusion of AUGTYRO® (repotrectinib) for ROS1+ NSCLC and Other Updates in China's National Reimbursement Drug List

Nov 21, 2024, 4:00 AM EST - 6 months ago

Zai Lab and Pfizer Announce Strategic Collaboration on the Novel Antibacterial Drug XACDURO® (Sulbactam-Durlobactam)

PFE

Nov 18, 2024, 9:15 AM EST - 7 months ago

Zai Lab Announces Anticipated Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters' Option to Purchase Additional American Depositary Shares

Nov 14, 2024, 7:43 PM EST - 7 months ago

Zai Lab Announces Pricing of Public Offering of American Depositary Shares

Nov 13, 2024, 4:12 PM EST - 7 months ago

Zai Lab Announces Proposed Public Offering of American Depositary Shares

Nov 12, 2024, 11:53 AM EST - 7 months ago

Zai Lab Limited (ZLAB) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 6:30 AM EST - 7 months ago

Zai Lab Announces Third Quarter 2024 Financial Results and Recent Corporate Updates

Nov 11, 2024, 7:30 AM EST - 7 months ago

Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China

ARGX

Oct 29, 2024, 7:30 AM EDT - 7 months ago

Zai Lab Reports Positive Topline Data from Phase 3 Bridging Trial Evaluating KarXT for the Treatment of Schizophrenia in China

Oct 24, 2024, 5:15 AM EDT - 7 months ago

ZL-1310, an Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC), Demonstrates Promising Objective Response Rates and Safety Profile in Extensive-Stage Small Cell Lung Cancer

Oct 18, 2024, 7:30 AM EDT - 8 months ago

Zai Lab Announces Participation in November and December Investor Conferences

Oct 17, 2024, 8:00 AM EDT - 8 months ago

Zai Lab to Host Webcast Presentation to Discuss Data from Early Clinical Program Evaluating Its Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310

Oct 16, 2024, 7:30 AM EDT - 8 months ago

Zai Lab to Announce Third Quarter 2024 Financial Results and Recent Corporate Updates on November 12, 2024

Oct 9, 2024, 7:00 AM EDT - 8 months ago

Zai Lab to Present Data from Phase 1 Trial of ZL-1310, Its Investigational Antibody-Drug Conjugate (ADC) for DLL3+ Solid Tumors, at EORTC-NCI-AACR Symposium (ENA) 2024

Sep 25, 2024, 4:36 AM EDT - 8 months ago

Zai Lab's Growth Strategy And China's Policy Reforms Set Path For Profitability By 2025

Sep 17, 2024, 1:32 PM EDT - 9 months ago

Zai Lab to Present Preclinical Data of ZL-1503, an IL-13/IL-31 Bispecific Antibody for the Treatment of Atopic Dermatitis, at EADV Congress 2024

Aug 27, 2024, 8:30 AM EDT - 9 months ago

Zai Lab to Present Preliminary Data From Phase 1 Trial of ZL-1218, an Investigational Anti-CCR8 Antibody for the Treatment of Advanced Solid Tumors, at ESMO Congress 2024

Aug 22, 2024, 7:30 AM EDT - 10 months ago

Zai Lab Announces Participation in September Investor Conferences

Aug 6, 2024, 4:05 PM EDT - 10 months ago

Zai Lab Announces Second Quarter 2024 Financial Results and Recent Corporate Updates

Jul 16, 2024, 12:15 AM EDT - 11 months ago

Zai Lab and argenx Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China

ARGX

Jul 15, 2024, 2:53 PM EDT - 11 months ago

Zai Lab-Supported Study Published in Cell Provides New Insights with Potential to Improve Treatment of HRD-Positive Ovarian Cancers, Including Through Combination PARP Inhibitor and CCR8 Therapy

Jul 10, 2024, 7:30 AM EDT - 11 months ago

Zai Lab to Announce Second Quarter 2024 Financial Results and Recent Corporate Updates on August 6, 2024